CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex

dc.contributorUniversidade Federal do Ceará (UFC)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:29:40Z
dc.date.available2014-05-27T11:29:40Z
dc.date.created2014-05-27T11:29:40Z
dc.date.issued2013-06-12
dc.identifierInternational Journal of Surgery, v. 11, n. 7, p. 549-553, 2013.
dc.identifier1743-9191
dc.identifier1743-9159
dc.identifierhttp://hdl.handle.net/11449/75638
dc.identifier10.1016/j.ijsu.2013.05.030
dc.identifierWOS:000321750800011
dc.identifier2-s2.0-84880329284
dc.identifier2-s2.0-84878686126
dc.identifier3587895085226224
dc.identifier4619588334582084
dc.identifier0000-0001-9200-5391
dc.description.abstractCDKN2A promoter hypermethylation has been widely related to many cancers. In astrocytomas, although CDKN2A (p16INK4A protein) is often inactivated, there are still some controversial issues regarding the mechanism by which this alteration occurs. Thus, we analyzed a series of astrocytomas to assess the association between CDKN2A expression and methylation of grade I-IV tumors (WHO) and clinicopathological parameters. DNA extracted from formalin-fixed paraffin-embedded material of 93 astrocytic tumors was available for CDKN2A promoter methylation analysis and p16INK4A expression by methylation-specific PCR and immunohistochemistry, respectively. A strong negative correlation between nuclear and cytoplasmic immunostaining and CDKN2A promoter methylation was found. Additionally, a significant negative correlation between CDKN2A promoter methylation and age was observed; also, female patients had statistically more CDKN2A methylated promoters (p=0.036) than men. In conclusion, CDKN2A inactivation by promoter methylation is a frequent event in astrocytomas and it is related to the age and sex of patients. © 2013 Surgical Associates Ltd.
dc.languageeng
dc.relationInternational Journal of Surgery
dc.relation2.693
dc.relation0,834
dc.relation0,834
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectAge
dc.subjectAstrocytic tumors
dc.subjectCDKN2A Methylation
dc.subjectExpression
dc.subjectP16
dc.subjectcyclin dependent kinase inhibitor 2A
dc.subjectDNA
dc.subjectadolescent
dc.subjectadult
dc.subjectage
dc.subjectaged
dc.subjectastrocytoma
dc.subjectchild
dc.subjectDNA extraction
dc.subjectfemale
dc.subjectgene expression
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectpreschool child
dc.subjectpriority journal
dc.subjectpromoter region
dc.subjectprotein methylation
dc.subjectschool child
dc.subjectsex difference
dc.titleCDKN2A promoter hypermethylation in astrocytomas is associated with age and sex
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución